Presentations on Inovio Biomedical's electroporation-delivered DNA vaccines

NewsGuard 100/100 Score

Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3rd Global Congress being held in Singapore October 4th – 6th.

Inovio representatives will be making the following presentations regarding electroporation-delivered DNA vaccines:

Delivering on the Promise of DNA Vaccines for HIV and Cancer:
From Bench to Clinical Data
David Weiner, Ph.D., Professor, University of Pennsylvania; Chairman, Scientific Advisory Board, Inovio Biomedical
Plenary Session 5, Novel Vaccines and Delivery Systems
Grand Ballroom
Monday, October 5
13:40

Development of Universal SynCon™ DNA Vaccines for Pandemic and Seasonal Flu
Niranjan Y. Sardesai, Ph.D., Senior VP, R & D, Inovio Biomedical
Breakout Session 1, JSV Sponsored Session and Influenza
Grand Ballroom
Monday, October 5
17:20

The presentations will include progress on programs in Inovio’s pipeline. The congress program consists of invited lectures and presentations selected from submitted abstracts broadly covering vaccine development. The key objectives of the Vaccine 3rd Global Congress are to:

  • provide a progressive state-of-the-art report for scientists, governmental authorities and healthcare workers
  • accelerate progress in the development of vaccines
  • encourage a prophylactic approach to healthcare.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals e-cigarette users with limited smoking history show similar DNA alterations as smokers